ESTRO 2024 - Abstract Book

S2591

Clinical - Urology

ESTRO 2024

The majority of patients (n = 125, 87.4%) received concomitant ADT with a median duration time of 12.0 months (IQR 9 – 12; available for 95 pts). The remaining patients could not undergo ADT due to comorbidities, according to clinical evaluation. At a median follow-up of 24 months, 85 (75.9%) patients showed not evidence of disease, while 27 (24%) were alive with disease (data available for 112 patients). Median PSA at last FU (data available for 109 pts – 75.6%) was 0.26 ng/ml. A total of 27 patients (18.75%) experienced a BP, with a median time of 23.3 months (IQR 16.38 – 31.58). Among them, 19 (70.4%) developed a CP of disease (2 local, 7 pelvic lymph nodal, and 6 bone relapses). All of them received concomitant ADT therapy at the time of UHRT treatment.

Out of the 19 patients who experienced a CP, 17 (89.4%) had only one factor of risk at diagnosis, with the most common (14/17) being GS. The remaining two (10.5%) patients had 2 and 3 risk factors, respectively.

Maximum registered toxicities (data available for 83 patients - 58%) are reported in Table 2. Six grade (G) ≥ 2 GU and 4 G ≥ 2 GI toxicities were reported. All G3 toxicities were solved at last follow -up.

Conclusion:

Additional data and longer follow-up are needed to give clearer indications to understand the subgroups of patients who deserve more aggressive treatments, including both systemic and regional (prophylactic pelvis irradiation) approach. However, these preliminary encouraging data suggest that UHRT could be considered as a safe and effective treatment option in patients with high and very high-risk disease, considering both the favorable toxicity profile and the rate of recurrences.